{"title": "Prof. Dr. rer. nat. Volker Schirrmacher P\u00e4diatrische H\u00e4mato-Onkologie - IOZK", "author": null, "url": "https://www.iozk.de/prof-dr-rer-nat-volker-schirrmacher/", "hostname": "iozk.de", "description": "Prof. Dr. rer. nat. Volker Schirrmacher hat die wissenschaftliche Leitung am IOZK.Er ist ein international anerkannter Pionier der Immuntherapie bei Krebs mit dem Schwerpunkt onkolytische Viren.", "sitename": "IOZK", "date": "2015-05-31", "id": null, "license": null, "body": null, "comments": "Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience/in Dendritic Cells, Glioblastoma, International Publications, IOZK Ver\u00f6ffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)\nCounteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy/in International Publications, IOZK Ver\u00f6ffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)\nSynergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;\nRandomized Controlled Immunotherapy Clinical Trials for GBM Challenged/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)\nMitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism/in International Publications, IOZK Ver\u00f6ffentlichungen /von 2020-11-22 / Biomedicines 2020 Nov;8(11)\nEvidence-Based Medicine in Oncology: Commercial Versus Patient Benefit/in International Publications, IOZK Ver\u00f6ffentlichungen /von 2020-07-23 / Biomedicines 2020 Jul;8(8)\nPosition paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646\nIOZK Analyse belegt gute Vertr\u00e4glichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)/in IOZK Ver\u00f6ffentlichungen /von IOZK\nAddition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)\nProf. Dr. Volker Schirrmacher ver\u00f6ffentlicht zwei wegweisende \u00dcbersichtsartikel zur Immuntherapie/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nCancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis/in International Publications, IOZK Ver\u00f6ffentlichungen /von 2020-03-16 / Biomedicines 2020 Mar;8(3)\nNew Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection/in Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)\nBreaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)\nProfessor Volker Schirrmacher vom K\u00f6lner IOZK er\u00f6ffnet die Tagung an der Universit\u00e4t zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie./in IOZK bei Fachtagungen /von IOZK\nFrom chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)/in International Publications, IOZK Ver\u00f6ffentlichungen /von 2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419\nInternational Journal of Oncology: \u201eVon der Chemotherapie zur biologischen Therapie\u201c, Prof. Dr. Volker Schirrmacher/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nIOZK-Artikel \u00fcber Heilversuche bei Glioblastom im Fachorgan: \u201eAustin Oncology Case Report\u201c/in IOZK Ver\u00f6ffentlichungen /von root\nIOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charit\u00e9 Berlin/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZK\nBuch Ver\u00f6ffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy/in IOZK Meldungen, IOZK Ver\u00f6ffentlichungen /von IOZK\nIOZK Artikel im International Journal of Molecular Sciences von Prof. Schirrmacher \u00fcber die Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung,/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nImmunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2017-05-20 / Int J Mol Sci 2017 May;18(5)\nIOZK Artikel von Prof. Schirrmacher in \u201eDeutsche Zeitschrift f\u00fcr Onkologie\u201c \u00fcber die Grundlagen der Immuntherapie/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nIOZK Artikel im Austin Oncology Case Reports \u00fcber Krebsimpfstoffe/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nArtikel von Prof Schirrmacher in Biomedicines: \u201eFifty Years of Clinical Application of Newcastle Disease Virus\u201c/in IOZK Meldungen, IOZK Ver\u00f6ffentlichungen /von IOZK\nFachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivit\u00e4t der Krebsbehandlung, Wiener klinisches Magazin/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nExpertenbericht von Prof. Dr. Schirrmacher, Wiener klinisches Magazin/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nBericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark/in IOZK Ver\u00f6ffentlichungen /von IOZK\nOncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71\nIOZK Fallstudie zum Langzeit\u00fcberleben einer Patientin mit Brustkrebs/in IOZK Meldungen, IOZK Ver\u00f6ffentlichungen /von IOZK\nBeitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift \u201eSkriptum\u201c/in IOZK In der Presse, IOZK Ver\u00f6ffentlichungen /von IOZK\nLong-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report/in Breast Cancer, Dendritic Cells, Hyperthermia, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2015-05-28 / Immunotherapy 2015;7(8):855-60\nProf. Dr. Schirrmacher ver\u00f6ffentlicht E-Book: Harnessing Oncolytic Virus-mediated Antitumor Immunity/in IOZK Meldungen, IOZK Ver\u00f6ffentlichungen /von IOZK\nStrong T\u2011cell costimulation can reactivate tumor antigen\u2011specific T cells in late\u2011stage metastasized colorectal carcinoma patients: results from a phase \u2160 clinical study/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2014-10-06 / Int. J. Oncol. 2015 Jan;46(1):71-7\nLong-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report/in Dendritic Cells, Hyperthermia, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus, Prostate Cancer /von 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406\nMultimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies/in Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2014-09-11 / Front Oncol 2014;4:224\nAutologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function/in Colorectal Cancer, Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen /von 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30\nOncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host/in Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75\nBispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53\nAnalysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204\nNewcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50\nImportance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98\nImportant role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504\nTargeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity/in Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29\nAntitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93\nTranscriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52\nOptimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17\nThe hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900\nPolarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus/in Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22\nActivation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21\nExpression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82\nCross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62\nRandomized clinical studies of anti-tumor vaccination: state of the art in 2008/in Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen /von 2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66\nNewcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2009-01-01 / Methods Mol. Biol. 2009;542:565-605\nTreatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study/in Breast Cancer, Dendritic Cells, International Publications, IOZK Ver\u00f6ffentlichungen /von 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900\nActivation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32\nRecombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80\nDetection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer/in Colorectal Cancer, International Publications, IOZK Ver\u00f6ffentlichungen /von 2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7\nEfficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial/in Colorectal Cancer, International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9\nAn effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89\nSecond International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007/in International Publications, IOZK Ver\u00f6ffentlichungen, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7\nHost mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application/in International Publications, Newcastle Disease Virus /von 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19\nRecombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy/in International Publications, Newcastle Disease Virus /von 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49\nRole of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma/in International Publications, Pancreatic Cancer /von 2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99\nTumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ/in Colorectal Cancer, International Publications /von 2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3\nTumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence/in International Publications, Newcastle Disease Virus /von 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38\nA tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes/in International Publications, Newcastle Disease Virus /von 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67\nTumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein/in International Publications, Newcastle Disease Virus /von 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84\nT-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine/in International Publications, Newcastle Disease Virus /von 2005-03-31 / Vaccine 2005 Mar;23(19):2439-53\nSelective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus/in International Publications, Newcastle Disease Virus /von 2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303\nSelective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein/in International Publications, Newcastle Disease Virus /von 2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-9\nAntitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells/in International Publications, Newcastle Disease Virus /von 2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61\nClinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory/in International Publications, Newcastle Disease Virus /von 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98\nAntitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81\nHigh cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules/in International Publications, Newcastle Disease Virus /von 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302\nImportance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus/in International Publications, Newcastle Disease Virus /von 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34\nTNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus/in International Publications, Newcastle Disease Virus /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21\nCognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo/in Breast Cancer, Dendritic Cells, International Publications /von 2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-83\nInfluence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer/in Breast Cancer, International Publications /von 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80\nEditorial von Prof. Dr. Volker Schirrmacher zum Beitrag \u201eImmuntherapeutische Strategien zur Behandlung solider Tumoren\u201c/in IOZK Ver\u00f6ffentlichungen /von IOZK\nHuman tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease Virus /von 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-93\nBeitrag mit Prof. Dr. Schirrmacher \u00fcber den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen/in Externe Meldungen, IOZK In der Presse /von IOZK\nGeneration of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells/in Dendritic Cells, International Publications /von 2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-53\nAntitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects/in International Publications, Newcastle Disease Virus /von 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52\nTumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures/in International Publications, Newcastle Disease Virus /von 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15\nHuman tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus/in International Publications, Newcastle Disease Virus /von 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73\nIntroduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus/in International Publications, Newcastle Disease Virus /von 1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15\nTumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer /von 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66", "commentsbody": null, "raw_text": null, "text": "Prof. Dr. rer. nat. Volker Schirrmacher\nWissenschaftlicher Leiter der Tumorimmunologie am IOZK\nWissenschaftlicher Leiter der Tumorimmunologie am IOZK\nProf. Dr. rer. nat. Volker Schirrmacher erhielt 1976 einen Ruf an das\n[Deutsche Krebsforschungszentrum (DKFZ)](https://de.wikipedia.org/wiki/Deutsches_Krebsforschungszentrum) in Heidelberg als Wissenschaftlicher Rat und Professor f\u00fcr Immunologie. 1979 habilitierte er sich in Immunologie in Heidelberg und 1986 wurde er ordentlicher Professor. Am DKFZ leitete er die Abteilung zellul\u00e4re Immunologie bis zu seiner Emeritierung 2008.\nSeit 2008 ist er am IOZK Wissenschaftlicher Leiter der Tumorimmunologie. Sein Wissenschaftliches \u0152uvre umfasst fast 400 Ver\u00f6ffentlichungen in internationalen Fachzeitschriften.\n1987 und 1988 war er Vorsitzender der\n[Sektion Experimentelle Krebsforschung bei der Deutschen Krebsgesellschaft](https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft/ueber-uns/organisation/sektion-b-arbeitsgemeinschaften/aek.html) und 1989/80 Pr\u00e4sident der [Metastasis Research Society](https://metastasis-research.org/). 2003 und 2004 vertrat er Deutschland bei der [European Association of Cancer Research](https://www.eacr.org/) (EACR). Von 2009 bis 2011 war er Pr\u00e4sident der Europ\u00e4ischen Gesellschaft f\u00fcr Angewandte Immunologie e.V. (EGAI).\n1982 erhielt er den Aronson-Preis und den Meyenburg-Preis und 1988 den Deutschen Krebspreis.\nEr ist ein international anerkannter Pionier der Immuntherapie bei Krebs mit dem Schwerpunkt onkolytische Viren. Gemeinsam mit den Naturwissenschaftlern und \u00c4rzten am IOZK arbeitet er an der systematischen Integration neuer wissenschaftlicher Erkenntnisse zur Weiterentwicklung der IOZK-Immuntherapie.\n\u201eViren sind als Ausl\u00f6ser verschiedener Krankheiten bekannt. Weniger bekannt ist jedoch, dass bestimmte Viren f\u00fcr die Behandlung von Krebs eingesetzt werden. Vor \u00fcber 100 Jahren beobachteten \u00c4rzte erstmals, dass Patienten nach Virusinfektionen von ihrem Krebsleiden geheilt waren.\u201c\nProf. Dr. rer. nat. Volker Schirrmacher\nThis post is also available in:\n[Englisch](https://www.iozk.de/en/prof-dr-rer-nat-volker-schirrmacher/) [Spanisch](https://www.iozk.de/es/prof-dr-rer-nat-volker-schirrmacher/) [Russisch](https://www.iozk.de/ru/prof-dr-rer-nat-volker-schirrmacher/)", "language": null, "image": null, "pagetype": "article", "links": ["https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.primomedico.com/fr/medecin/iozk-centre-immunologie-et-oncologie-de-cologne/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.primomedico.com/ar/tabib/iozk-mrkz-elm-almnaep-alsrtany-fy-koln/", "mailto:info@iozk.de", "https://www.iozk.de/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/en/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/es/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/ru/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/pl/", "https://www.iozk.de/", "/", "#", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "#", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "#", "https://www.iozk.de/iozk-publikationen/", "https://www.iozk.de/publikationen/", "https://www.iozk.de/fachwissen/", "https://www.iozk.de/aktuelles/", "https://www.iozk.de/kontakt/", "?s=", "#", "https://de.wikipedia.org/wiki/Deutsches_Krebsforschungszentrum", "https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft/ueber-uns/organisation/sektion-b-arbeitsgemeinschaften/aek.html", "https://metastasis-research.org/", "https://www.eacr.org/", "https://de.wikipedia.org/wiki/Volker_Schirrmacher", "https://www.iozk.de/2023/02/individualized-multimodal-immunotherapy-for-adults-with-idh1-wild-type-gbm-a-single-institute-experience/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2023/02/individualized-multimodal-immunotherapy-for-adults-with-idh1-wild-type-gbm-a-single-institute-experience/", "https://www.iozk.de/2022/10/counteracting-immunosuppression-in-the-tumor-microenvironment-by-oncolytic-newcastle-disease-virus-and-cellular-immunotherapy/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2022/10/counteracting-immunosuppression-in-the-tumor-microenvironment-by-oncolytic-newcastle-disease-virus-and-cellular-immunotherapy/", "https://www.iozk.de/2022/02/synergy-between-tmz-and-individualized-multimodal-immunotherapy-to-improve-overall-survival-of-idh1-wild-type-mgmt-promoter-unmethylated-gbm-patients/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/hyperthermia/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2022/02/synergy-between-tmz-and-individualized-multimodal-immunotherapy-to-improve-overall-survival-of-idh1-wild-type-mgmt-promoter-unmethylated-gbm-patients/", "https://www.iozk.de/2020/12/randomized-controlled-immunotherapy-clinical-trials-for-gbm-challenged/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/hyperthermia/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2020/12/randomized-controlled-immunotherapy-clinical-trials-for-gbm-challenged/", "https://www.iozk.de/2020/11/mitochondria-at-work-new-insights-into-regulation-and-dysregulation-of-cellular-energy-supply-and-metabolism/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2020/11/mitochondria-at-work-new-insights-into-regulation-and-dysregulation-of-cellular-energy-supply-and-metabolism/", "https://www.iozk.de/2020/07/evidence-based-medicine-in-oncology-commercial-versus-patient-benefit/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2020/07/evidence-based-medicine-in-oncology-commercial-versus-patient-benefit/", "https://www.iozk.de/2020/06/position-paper-new-insights-into-the-immunobiology-and-dynamics-of-tumor-host-interactions-require-adaptations-of-clinical-studies/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/hyperthermia/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2020/06/position-paper-new-insights-into-the-immunobiology-and-dynamics-of-tumor-host-interactions-require-adaptations-of-clinical-studies/", "https://www.iozk.de/2020/06/iozk-analyse-belegt-gute-vertraeglichkeit-der-iozk-immuntherapie-beim-diffusen-intrinsischen-pontinen-gliom-dipg/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2020/06/iozk-analyse-belegt-gute-vertraeglichkeit-der-iozk-immuntherapie-beim-diffusen-intrinsischen-pontinen-gliom-dipg/", "https://www.iozk.de/2020/05/addition-of-multimodal-immunotherapy-to-combination-treatment-strategies-for-children-with-dipg-a-single-institution-experience/", "https://www.iozk.de/category/publications/brain-tumors-in-children/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/hyperthermia/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2020/05/addition-of-multimodal-immunotherapy-to-combination-treatment-strategies-for-children-with-dipg-a-single-institution-experience/", "https://www.iozk.de/2020/03/prof-dr-volker-schirrmacher-veroeffentlicht-zwei-wegweisende-uebersichtsartikel-zur-immuntherapie/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2020/03/prof-dr-volker-schirrmacher-veroeffentlicht-zwei-wegweisende-uebersichtsartikel-zur-immuntherapie/", "https://www.iozk.de/2020/03/cancer-vaccines-and-oncolytic-viruses-exert-profoundly-lower-side-effects-in-cancer-patients-than-other-systemic-therapies-a-comparative-analysis/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2020/03/cancer-vaccines-and-oncolytic-viruses-exert-profoundly-lower-side-effects-in-cancer-patients-than-other-systemic-therapies-a-comparative-analysis/", "https://www.iozk.de/2020/03/new-insights-into-mechanisms-of-long-term-protective-anti-tumor-immunity-induced-by-cancer-vaccines-modified-by-virus-infection/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2020/03/new-insights-into-mechanisms-of-long-term-protective-anti-tumor-immunity-induced-by-cancer-vaccines-modified-by-virus-infection/", "https://www.iozk.de/2019/08/breaking-therapy-resistance-an-update-on-oncolytic-newcastle-disease-virus-for-improvements-of-cancer-therapy/", "https://www.iozk.de/category/publications/checkpoint-inhibitors/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2019/08/breaking-therapy-resistance-an-update-on-oncolytic-newcastle-disease-virus-for-improvements-of-cancer-therapy/", "https://www.iozk.de/2019/05/professor-volker-schirrmacher-vom-koelner-iozk-eroeffnet-die-tagung-mit-seinem-vortrag-zur-erforschung-onkolytischer-viren-im-zusammenhang-der-individuellen-krebs-immuntherapie/", "https://www.iozk.de/category/iozk-aktuelles/iozk-bei-fachtagungen/", "#", "https://www.iozk.de/2019/05/professor-volker-schirrmacher-vom-koelner-iozk-eroeffnet-die-tagung-mit-seinem-vortrag-zur-erforschung-onkolytischer-viren-im-zusammenhang-der-individuellen-krebs-immuntherapie/", "https://www.iozk.de/2018/12/from-chemotherapy-to-biological-therapy-a-review-of-novel-concepts-to-reduce-the-side-effects-of-systemic-cancer-treatment-review/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2018/12/from-chemotherapy-to-biological-therapy-a-review-of-novel-concepts-to-reduce-the-side-effects-of-systemic-cancer-treatment-review/", "https://www.iozk.de/2018/12/von-der-chemotherapie-zur-biologischen-therapie-eine-ueberpruefung-neuartiger-konzepte-zur-reduktion-der-nebenwirkungen-bei-einer-systemischen-krebsbehandlungveroeffentlichung-von-prof-dr-volker-sc/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2018/12/von-der-chemotherapie-zur-biologischen-therapie-eine-ueberpruefung-neuartiger-konzepte-zur-reduktion-der-nebenwirkungen-bei-einer-systemischen-krebsbehandlungveroeffentlichung-von-prof-dr-volker-sc/", "https://www.iozk.de/2018/07/iozk-artikel-ueber-heilversuche-bei-glioblastom-im-fachorgan-austin-oncology-case-report/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2018/07/iozk-artikel-ueber-heilversuche-bei-glioblastom-im-fachorgan-austin-oncology-case-report/", "https://www.iozk.de/2018/05/iozk-vortrag-an-der-konferenz-der-esho-modulierte-elektro-hyperthermie-bei-kindern-mit-dipg/", "https://www.iozk.de/category/iozk-aktuelles/iozk-bei-fachtagungen/", "https://www.iozk.de/category/iozk-aktuelles/iozk-meldungen/", "#", "https://www.iozk.de/2018/05/iozk-vortrag-an-der-konferenz-der-esho-modulierte-elektro-hyperthermie-bei-kindern-mit-dipg/", "https://www.iozk.de/2018/01/buch-veroeffentlichung-von-prof-dr-schirrmacher-quo-vadis-cancer-therapy/", "https://www.iozk.de/category/iozk-aktuelles/iozk-meldungen/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2018/01/buch-veroeffentlichung-von-prof-dr-schirrmacher-quo-vadis-cancer-therapy/", "https://www.iozk.de/2017/07/iozk-artikel-im-international-journal-of-molecular-sciences-von-prof-schirrmacher-ueber-die-rolle-des-newcastle-disease-virus-im-rahmen-der-tumorimpfung/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2017/07/iozk-artikel-im-international-journal-of-molecular-sciences-von-prof-schirrmacher-ueber-die-rolle-des-newcastle-disease-virus-im-rahmen-der-tumorimpfung/", "https://www.iozk.de/2017/05/immunobiology-of-newcastle-disease-virus-and-its-use-for-prophylactic-vaccination-in-poultry-and-as-adjuvant-for-therapeutic-vaccination-in-cancer-patients/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2017/05/immunobiology-of-newcastle-disease-virus-and-its-use-for-prophylactic-vaccination-in-poultry-and-as-adjuvant-for-therapeutic-vaccination-in-cancer-patients/", "https://www.iozk.de/2017/05/iozk-artikel-von-prof-schirmacher-in-deutsche-zeitschrift-fuer-onkologie-ueber-die-grundlagen-der-immuntherapie/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2017/05/iozk-artikel-von-prof-schirmacher-in-deutsche-zeitschrift-fuer-onkologie-ueber-die-grundlagen-der-immuntherapie/", "https://www.iozk.de/2017/03/iozk-artikel-im-austin-oncology-case-reports-ueber-krebsimpfstoffe/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2017/03/iozk-artikel-im-austin-oncology-case-reports-ueber-krebsimpfstoffe/", "https://www.iozk.de/2016/08/artikel-von-prof-schirrmacher-in-biomedicines-50-jahre-klinische-anwendung-des-newcastle-disease-virus/", "https://www.iozk.de/category/iozk-aktuelles/iozk-meldungen/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2016/08/artikel-von-prof-schirrmacher-in-biomedicines-50-jahre-klinische-anwendung-des-newcastle-disease-virus/", "https://www.iozk.de/2016/06/fachbeitrag-von-prof-schirrmacher-zur-effizienz-und-effektivitaet-der-krebsbehandlung-wiener-klinisches-magazin/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2016/06/fachbeitrag-von-prof-schirrmacher-zur-effizienz-und-effektivitaet-der-krebsbehandlung-wiener-klinisches-magazin/", "https://www.iozk.de/2016/03/expertenbericht-von-prof-dr-schirrmacher-wiener-klinisches-magazin/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2016/03/expertenbericht-von-prof-dr-schirrmacher-wiener-klinisches-magazin/", "https://www.iozk.de/2015/10/bericht-von-prof-dr-schirrmacher-im-international-journal-of-oncology-zu-den-erkenntnissen-der-tumor-reaktiven-t-zell-memory-im-knochenmark/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2015/10/bericht-von-prof-dr-schirrmacher-im-international-journal-of-oncology-zu-den-erkenntnissen-der-tumor-reaktiven-t-zell-memory-im-knochenmark/", "https://www.iozk.de/2015/10/oncolytic-newcastle-disease-virus-as-a-prospective-anti-cancer-therapy-a-biologic-agent-with-potential-to-break-therapy-resistance/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2015/10/oncolytic-newcastle-disease-virus-as-a-prospective-anti-cancer-therapy-a-biologic-agent-with-potential-to-break-therapy-resistance/", "https://www.iozk.de/2015/06/iozk-fallstudie-zum-langzeitueberleben-einer-patientin-mit-brustkrebs/", "https://www.iozk.de/category/iozk-aktuelles/iozk-meldungen/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2015/06/iozk-fallstudie-zum-langzeitueberleben-einer-patientin-mit-brustkrebs/", "https://www.iozk.de/2015/06/beitrag-von-prof-dr-schirrmacher-in-der-wiener-medizinischen-wochenschrift-skriptum/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2015/06/beitrag-von-prof-dr-schirrmacher-in-der-wiener-medizinischen-wochenschrift-skriptum/", "https://www.iozk.de/2015/05/long-term-survival-of-a-breast-cancer-patient-with-extensive-liver-metastases-upon-immune-and-virotherapy-a-case-report/", "https://www.iozk.de/category/publications/breast-cancer/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/hyperthermia/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2015/05/long-term-survival-of-a-breast-cancer-patient-with-extensive-liver-metastases-upon-immune-and-virotherapy-a-case-report/", "https://www.iozk.de/2014/11/prof-dr-schirrmacher-veroeffentlicht-e-book-harnessing-oncolytic-virus-mediated-antitumor-immunity/", "https://www.iozk.de/category/iozk-aktuelles/iozk-meldungen/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2014/11/prof-dr-schirrmacher-veroeffentlicht-e-book-harnessing-oncolytic-virus-mediated-antitumor-immunity/", "https://www.iozk.de/2014/10/strong-t%e2%80%91cell-costimulation-can-reactivate-tumor-antigen%e2%80%91specific-t-cells-in-late%e2%80%91stage-metastasized-colorectal-carcinoma-patients-results-from-a-phase-%e2%85%b0-clinical-stud/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2014/10/strong-t%e2%80%91cell-costimulation-can-reactivate-tumor-antigen%e2%80%91specific-t-cells-in-late%e2%80%91stage-metastasized-colorectal-carcinoma-patients-results-from-a-phase-%e2%85%b0-clinical-stud/", "https://www.iozk.de/2014/10/long-term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno-and-virotherapy-a-case-report/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/hyperthermia/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "https://www.iozk.de/category/publications/prostate-cancer/", "#", "https://www.iozk.de/2014/10/long-term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno-and-virotherapy-a-case-report/", "https://www.iozk.de/2014/09/multimodal-cancer-therapy-involving-oncolytic-newcastle-disease-virus-autologous-immune-cells-and-bi-specific-antibodies/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2014/09/multimodal-cancer-therapy-involving-oncolytic-newcastle-disease-virus-autologous-immune-cells-and-bi-specific-antibodies/", "https://www.iozk.de/2014/01/autologous-tumor-cell-vaccines-for-post-operative-active-specific-immunotherapy-of-colorectal-carcinoma-long-term-patient-survival-and-mechanism-of-function/", "https://www.iozk.de/category/publications/colorectal-cancer/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2014/01/autologous-tumor-cell-vaccines-for-post-operative-active-specific-immunotherapy-of-colorectal-carcinoma-long-term-patient-survival-and-mechanism-of-function/", "https://www.iozk.de/2013/07/oncolytic-newcastle-disease-virus-as-cutting-edge-between-tumor-and-host/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2013/07/oncolytic-newcastle-disease-virus-as-cutting-edge-between-tumor-and-host/", "https://www.iozk.de/2013/02/bispecific-antibodies-and-trispecific-immunocytokines-for-targeting-the-immune-system-against-cancer-preparing-for-the-future/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2013/02/bispecific-antibodies-and-trispecific-immunocytokines-for-targeting-the-immune-system-against-cancer-preparing-for-the-future/", "https://www.iozk.de/2012/01/analysis-of-three-properties-of-newcastle-disease-virus-for-fighting-cancer-tumor-selective-replication-antitumor-cytotoxicity-and-immunostimulation/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2012/01/analysis-of-three-properties-of-newcastle-disease-virus-for-fighting-cancer-tumor-selective-replication-antitumor-cytotoxicity-and-immunostimulation/", "https://www.iozk.de/2011/11/newcastle-disease-virus-induces-pro-inflammatory-conditions-and-type-i-interferon-for-counter-acting-treg-activity/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2011/11/newcastle-disease-virus-induces-pro-inflammatory-conditions-and-type-i-interferon-for-counter-acting-treg-activity/", "https://www.iozk.de/2011/10/importance-of-retinoic-acid-inducible-gene-i-and-of-receptor-for-type-i-interferon-for-cellular-resistance-to-infection-by-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2011/10/importance-of-retinoic-acid-inducible-gene-i-and-of-receptor-for-type-i-interferon-for-cellular-resistance-to-infection-by-newcastle-disease-virus/", "https://www.iozk.de/2011/05/important-role-of-interferon-regulatory-factor-irf-3-in-the-interferon-response-of-mouse-macrophages-upon-infection-by-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2011/05/important-role-of-interferon-regulatory-factor-irf-3-in-the-interferon-response-of-mouse-macrophages-upon-infection-by-newcastle-disease-virus/", "https://www.iozk.de/2011/03/targeting-of-il-2-and-gm-csf-immunocytokines-to-a-tumor-vaccine-leads-to-increased-anti-tumor-activity/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2011/03/targeting-of-il-2-and-gm-csf-immunocytokines-to-a-tumor-vaccine-leads-to-increased-anti-tumor-activity/", "https://www.iozk.de/2010/12/antitumor-vaccination-by-newcastle-disease-virus-hemagglutinin-neuraminidase-plasmid-dna-application-changes-in-tumor-microenvironment-and-activation-of-innate-anti-tumor-immunity/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2010/12/antitumor-vaccination-by-newcastle-disease-virus-hemagglutinin-neuraminidase-plasmid-dna-application-changes-in-tumor-microenvironment-and-activation-of-innate-anti-tumor-immunity/", "https://www.iozk.de/2010/12/transcriptome-analysis-and-cytokine-profiling-of-naive-t-cells-stimulated-by-a-tumor-vaccine-via-cd3-and-cd25/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2010/12/transcriptome-analysis-and-cytokine-profiling-of-naive-t-cells-stimulated-by-a-tumor-vaccine-via-cd3-and-cd25/", "https://www.iozk.de/2010/11/optimization-studies-for-the-coupling-of-bispecific-antibodies-to-viral-anchor-molecules-of-a-tumor-vaccine/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2010/11/optimization-studies-for-the-coupling-of-bispecific-antibodies-to-viral-anchor-molecules-of-a-tumor-vaccine/", "https://www.iozk.de/2010/08/the-hemagglutinin-neuraminidase-gene-of-newcastle-disease-virus-a-powerful-molecular-adjuvant-for-dna-anti-tumor-vaccination/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2010/08/the-hemagglutinin-neuraminidase-gene-of-newcastle-disease-virus-a-powerful-molecular-adjuvant-for-dna-anti-tumor-vaccination/", "https://www.iozk.de/2009/09/polarization-of-human-monocyte-derived-dendritic-cells-to-dc1-by-in-vitro-stimulation-with-newcastle-disease-virus/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2009/09/polarization-of-human-monocyte-derived-dendritic-cells-to-dc1-by-in-vitro-stimulation-with-newcastle-disease-virus/", "https://www.iozk.de/2009/06/activation-of-natural-killer-cells-by-newcastle-disease-virus-hemagglutinin-neuraminidase/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2009/06/activation-of-natural-killer-cells-by-newcastle-disease-virus-hemagglutinin-neuraminidase/", "https://www.iozk.de/2009/04/expression-of-rig-i-irf3-ifn-beta-and-irf7-determines-resistance-or-susceptibility-of-cells-to-infection-by-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2009/04/expression-of-rig-i-irf3-ifn-beta-and-irf7-determines-resistance-or-susceptibility-of-cells-to-infection-by-newcastle-disease-virus/", "https://www.iozk.de/2009/04/cross-infection-of-tumor-cells-by-contact-with-t-lymphocytes-loaded-with-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2009/04/cross-infection-of-tumor-cells-by-contact-with-t-lymphocytes-loaded-with-newcastle-disease-virus/", "https://www.iozk.de/2009/01/randomized-clinical-studies-of-anti-tumor-vaccination-state-of-the-art-in-2008/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2009/01/randomized-clinical-studies-of-anti-tumor-vaccination-state-of-the-art-in-2008/", "https://www.iozk.de/2009/01/newcastle-disease-virus-a-promising-vector-for-viral-therapy-immune-therapy-and-gene-therapy-of-cancer/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2009/01/newcastle-disease-virus-a-promising-vector-for-viral-therapy-immune-therapy-and-gene-therapy-of-cancer/", "https://www.iozk.de/2008/11/treatment-of-advanced-metastasized-breast-cancer-with-bone-marrow-derived-tumour-reactive-memory-t-cells-a-pilot-clinical-study/", "https://www.iozk.de/category/publications/breast-cancer/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2008/11/treatment-of-advanced-metastasized-breast-cancer-with-bone-marrow-derived-tumour-reactive-memory-t-cells-a-pilot-clinical-study/", "https://www.iozk.de/2008/10/activation-of-human-t-cells-by-a-tumor-vaccine-infected-with-recombinant-newcastle-disease-virus-producing-il-2/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2008/10/activation-of-human-t-cells-by-a-tumor-vaccine-infected-with-recombinant-newcastle-disease-virus-producing-il-2/", "https://www.iozk.de/2008/06/recombinant-newcastle-disease-virus-expressing-human-interleukin-2-serves-as-a-potential-candidate-for-tumor-therapy/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2008/06/recombinant-newcastle-disease-virus-expressing-human-interleukin-2-serves-as-a-potential-candidate-for-tumor-therapy/", "https://www.iozk.de/2008/06/detection-and-functional-analysis-of-tumor-infiltrating-t-lymphocytes-til-in-liver-metastases-from-colorectal-cancer/", "https://www.iozk.de/category/publications/colorectal-cancer/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2008/06/detection-and-functional-analysis-of-tumor-infiltrating-t-lymphocytes-til-in-liver-metastases-from-colorectal-cancer/", "https://www.iozk.de/2008/05/efficiency-of-adjuvant-active-specific-immunization-with-newcastle-disease-virus-modified-tumor-cells-in-colorectal-cancer-patients-following-resection-of-liver-metastases-results-of-a-prospective-ra/", "https://www.iozk.de/category/publications/colorectal-cancer/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2008/05/efficiency-of-adjuvant-active-specific-immunization-with-newcastle-disease-virus-modified-tumor-cells-in-colorectal-cancer-patients-following-resection-of-liver-metastases-results-of-a-prospective-ra/", "https://www.iozk.de/2008/04/an-effective-tumor-vaccine-optimized-for-costimulation-via-bispecific-and-trispecific-fusion-proteins/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2008/04/an-effective-tumor-vaccine-optimized-for-costimulation-via-bispecific-and-trispecific-fusion-proteins/", "https://www.iozk.de/2008/02/second-international-conference-on-cancer-vaccines-adjuvants-delivery-for-the-next-decade-cvadd-heidelberg-germany-10-12-october-2007/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2008/02/second-international-conference-on-cancer-vaccines-adjuvants-delivery-for-the-next-decade-cvadd-heidelberg-germany-10-12-october-2007/", "https://www.iozk.de/2007/11/host-mediated-anti-tumor-effect-of-oncolytic-newcastle-disease-virus-after-locoregional-application/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2007/11/host-mediated-anti-tumor-effect-of-oncolytic-newcastle-disease-virus-after-locoregional-application/", "https://www.iozk.de/2007/10/recombinant-newcastle-disease-virus-ndv-with-inserted-gene-coding-for-gm-csf-as-a-new-vector-for-cancer-immunogene-therapy/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2007/10/recombinant-newcastle-disease-virus-ndv-with-inserted-gene-coding-for-gm-csf-as-a-new-vector-for-cancer-immunogene-therapy/", "https://www.iozk.de/2007/07/role-of-tumor-endothelium-in-cd4-cd25-regulatory-t-cell-infiltration-of-human-pancreatic-carcinoma/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/pancreatic-cancer/", "#", "https://www.iozk.de/2007/07/role-of-tumor-endothelium-in-cd4-cd25-regulatory-t-cell-infiltration-of-human-pancreatic-carcinoma/", "https://www.iozk.de/2006/12/tumor-infiltrating-t-lymphocytes-in-colorectal-cancer-tumor-selective-activation-and-cytotoxic-activity-in-situ/", "https://www.iozk.de/category/publications/colorectal-cancer/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2006/12/tumor-infiltrating-t-lymphocytes-in-colorectal-cancer-tumor-selective-activation-and-cytotoxic-activity-in-situ/", "https://www.iozk.de/2006/07/tumor-selective-replication-of-newcastle-disease-virus-association-with-defects-of-tumor-cells-in-antiviral-defence/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2006/07/tumor-selective-replication-of-newcastle-disease-virus-association-with-defects-of-tumor-cells-in-antiviral-defence/", "https://www.iozk.de/2006/02/a-tumor-vaccine-containing-anti-cd3-and-anti-cd28-bispecific-antibodies-triggers-strong-and-durable-antitumor-activity-in-human-lymphocytes/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2006/02/a-tumor-vaccine-containing-anti-cd3-and-anti-cd28-bispecific-antibodies-triggers-strong-and-durable-antitumor-activity-in-human-lymphocytes/", "https://www.iozk.de/2005/08/tumor-targeted-gene-transfer-in-vivo-via-recombinant-newcastle-disease-virus-modified-by-a-bispecific-fusion-protein/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2005/08/tumor-targeted-gene-transfer-in-vivo-via-recombinant-newcastle-disease-virus-modified-by-a-bispecific-fusion-protein/", "https://www.iozk.de/2005/03/t-cell-triggering-by-cd3-and-cd28-binding-molecules-linked-to-a-human-virus-modified-tumor-cell-vaccine/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2005/03/t-cell-triggering-by-cd3-and-cd28-binding-molecules-linked-to-a-human-virus-modified-tumor-cell-vaccine/", "https://www.iozk.de/2005/03/selective-gene-transfer-in-vitro-to-tumor-cells-via-recombinant-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2005/03/selective-gene-transfer-in-vitro-to-tumor-cells-via-recombinant-newcastle-disease-virus/", "https://www.iozk.de/2005/02/selective-gene-transfer-to-tumor-cells-by-recombinant-newcastle-disease-virus-via-a-bispecific-fusion-protein/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2005/02/selective-gene-transfer-to-tumor-cells-by-recombinant-newcastle-disease-virus-via-a-bispecific-fusion-protein/", "https://www.iozk.de/2004/11/antitumor-vaccination-in-patients-with-head-and-neck-squamous-cell-carcinomas-with-autologous-virus-modified-tumor-cells/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2004/11/antitumor-vaccination-in-patients-with-head-and-neck-squamous-cell-carcinomas-with-autologous-virus-modified-tumor-cells/", "https://www.iozk.de/2004/10/clinical-trials-of-antitumor-vaccination-with-an-autologous-tumor-cell-vaccine-modified-by-virus-infection-improvement-of-patient-survival-based-on-improved-antitumor-immune-memory/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2004/10/clinical-trials-of-antitumor-vaccination-with-an-autologous-tumor-cell-vaccine-modified-by-virus-infection-improvement-of-patient-survival-based-on-improved-antitumor-immune-memory/", "https://www.iozk.de/2004/09/antitumor-vaccination-of-patients-with-glioblastoma-multiforme-a-pilot-study-to-assess-feasibility-safety-and-clinical-benefit/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2004/09/antitumor-vaccination-of-patients-with-glioblastoma-multiforme-a-pilot-study-to-assess-feasibility-safety-and-clinical-benefit/", "https://www.iozk.de/2004/08/high-cell-surface-expression-of-newcastle-disease-virus-proteins-via-replicon-vectors-demonstrates-syncytia-forming-activity-of-f-and-fusion-promotion-activity-of-hn-molecules/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2004/08/high-cell-surface-expression-of-newcastle-disease-virus-proteins-via-replicon-vectors-demonstrates-syncytia-forming-activity-of-f-and-fusion-promotion-activity-of-hn-molecules/", "https://www.iozk.de/2004/03/importance-of-serine-200-for-functional-activities-of-the-hemagglutinin-neuraminidase-protein-of-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2004/03/importance-of-serine-200-for-functional-activities-of-the-hemagglutinin-neuraminidase-protein-of-newcastle-disease-virus/", "https://www.iozk.de/2003/02/tnf-related-apoptosis-inducing-ligand-mediates-tumoricidal-activity-of-human-monocytes-stimulated-by-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2003/02/tnf-related-apoptosis-inducing-ligand-mediates-tumoricidal-activity-of-human-monocytes-stimulated-by-newcastle-disease-virus/", "https://www.iozk.de/2003/01/cognate-interactions-between-memory-t-cells-and-tumor-antigen-presenting-dendritic-cells-from-bone-marrow-of-breast-cancer-patients-bidirectional-cell-stimulation-survival-and-antitumor-activity-in/", "https://www.iozk.de/category/publications/breast-cancer/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2003/01/cognate-interactions-between-memory-t-cells-and-tumor-antigen-presenting-dendritic-cells-from-bone-marrow-of-breast-cancer-patients-bidirectional-cell-stimulation-survival-and-antitumor-activity-in/", "https://www.iozk.de/2003/01/influence-of-adjuvant-hormone-therapy-and-chemotherapy-on-the-immune-system-analysed-in-the-bone-marrow-of-patients-with-breast-cancer/", "https://www.iozk.de/category/publications/breast-cancer/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2003/01/influence-of-adjuvant-hormone-therapy-and-chemotherapy-on-the-immune-system-analysed-in-the-bone-marrow-of-patients-with-breast-cancer/", "https://www.iozk.de/2002/12/editorial-von-prof-dr-volker-schirrmacher-zum-beitrag-immuntherapeutische-strategien-zur-behandlung-solider-tumoren/", "https://www.iozk.de/category/iozk-aktuelles/iozk-veroeffentlichungen/", "#", "https://www.iozk.de/2002/12/editorial-von-prof-dr-volker-schirrmacher-zum-beitrag-immuntherapeutische-strategien-zur-behandlung-solider-tumoren/", "https://www.iozk.de/2002/07/human-tumor-cell-infection-by-newcastle-disease-virus-leads-to-upregulation-of-hla-and-cell-adhesion-molecules-and-to-induction-of-interferons-chemokines-and-finally-apoptosis/", "https://www.iozk.de/category/publications/breast-cancer/", "https://www.iozk.de/category/publications/colorectal-cancer/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2002/07/human-tumor-cell-infection-by-newcastle-disease-virus-leads-to-upregulation-of-hla-and-cell-adhesion-molecules-and-to-induction-of-interferons-chemokines-and-finally-apoptosis/", "https://www.iozk.de/2002/02/beitrag-mit-prof-dr-schirrmacher-ueber-den-stellenwert-der-dendritischen-zellen-im-einsatz-gegen-krebszellen/", "https://www.iozk.de/category/iozk-aktuelles/externe-meldungen/", "https://www.iozk.de/category/iozk-aktuelles/iozk-in-der-presse/", "#", "https://www.iozk.de/2002/02/beitrag-mit-prof-dr-schirrmacher-ueber-den-stellenwert-der-dendritischen-zellen-im-einsatz-gegen-krebszellen/", "https://www.iozk.de/2002/02/generation-of-dendritic-cells-from-human-bone-marrow-mononuclear-cells-advantages-for-clinical-application-in-comparison-to-peripheral-blood-monocyte-derived-cells/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/", "#", "https://www.iozk.de/2002/02/generation-of-dendritic-cells-from-human-bone-marrow-mononuclear-cells-advantages-for-clinical-application-in-comparison-to-peripheral-blood-monocyte-derived-cells/", "https://www.iozk.de/2001/05/antitumor-effects-of-newcastle-disease-virus-in-vivo-local-versus-systemic-effects/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/2001/05/antitumor-effects-of-newcastle-disease-virus-in-vivo-local-versus-systemic-effects/", "https://www.iozk.de/1999/02/tumor-stimulator-cell-modification-by-infection-with-newcastle-disease-virus-analysis-of-effects-and-mechanism-in-mltc-cml-cultures/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/1999/02/tumor-stimulator-cell-modification-by-infection-with-newcastle-disease-virus-analysis-of-effects-and-mechanism-in-mltc-cml-cultures/", "https://www.iozk.de/1999/01/human-tumor-cell-modification-by-virus-infection-an-efficient-and-safe-way-to-produce-cancer-vaccine-with-pleiotropic-immune-stimulatory-properties-when-using-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/1999/01/human-tumor-cell-modification-by-virus-infection-an-efficient-and-safe-way-to-produce-cancer-vaccine-with-pleiotropic-immune-stimulatory-properties-when-using-newcastle-disease-virus/", "https://www.iozk.de/1998/12/introduction-of-adhesive-and-costimulatory-immune-functions-into-tumor-cells-by-infection-with-newcastle-disease-virus/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "#", "https://www.iozk.de/1998/12/introduction-of-adhesive-and-costimulatory-immune-functions-into-tumor-cells-by-infection-with-newcastle-disease-virus/", "https://www.iozk.de/1997/04/tumor-cell-number-and-viability-as-quality-and-efficacy-parameters-of-autologous-virus-modified-cancer-vaccines-in-patients-with-breast-or-ovarian-cancer/", "https://www.iozk.de/category/publications/breast-cancer/", "https://www.iozk.de/category/publications/", "https://www.iozk.de/category/publications/newcastle-disease-virus/", "https://www.iozk.de/category/publications/ovarian-cancer/", "#", "https://www.iozk.de/1997/04/tumor-cell-number-and-viability-as-quality-and-efficacy-parameters-of-autologous-virus-modified-cancer-vaccines-in-patients-with-breast-or-ovarian-cancer/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://portal.dnb.de/opac.htm?method=simpleSearch&query=1102814024", "https://www.iozk.de/portfolio-item/virotherapie-mit-viren-gegen-den-krebs/", "https://www.iozk.de/portfolio-item/dendritische-zellen-informieren-das-immunsystem/", "https://www.iozk.de/en/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/es/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/ru/prof-dr-rer-nat-volker-schirrmacher/", "tel:004922142039925", "mailto:info@iozk.de", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/impressum/", "https://www.iozk.de/datenschutzerklaerung/", "https://www.iozk.de/datenschutz/#BorCook", "https://www.iozk.de/presse/", "#top"]}